- NEUTRAL
Quarterly Revenue SELLAS Life Sciences Grp Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Quarterly Net Profit SELLAS Life Sciences Grp Inc Jun-2026 Quarterly Net Profit is $-10 Million which is growth of -45.5% YoY.
9.98-1.36(-11.99%)
15.8M
XNAS Volume
High volume+loss today
XNAS 16 Oct, 2026 5:30 PM (EDT)
SELLAS Life Sciences Grp Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
SELLAS Life Sciences Grp Inc quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | ||||||||||||||
Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | ||||
Gross Profit | - | - | - | - | - | - | - | - | - | - | ||||
| 10.6 | 9.3 | 8.3 | 7.1 | 6.9 | 6.1 | 6.9 | 7.3 | 7.6 | 9.6 | 8.2 | 9.4 | 9.1 | ||
Operating Profit | -10.6 | -9.3 | -8.3 | -7.1 | -6.9 | -6.1 | -6.9 | -7.3 | -7.6 | -9.6 | -8.2 | -9.4 | -9.1 | |
| 1 | 0.8 | 0.6 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0 | 0.1 | 0.2 | ||
Profit Before Tax | -9.6 | -8.4 | -7.7 | -6.8 | -6.6 | -5.8 | -6.7 | -7.1 | -7.5 | -9.6 | -8.1 | -9.3 | -8.8 | |
Tax | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| -9.6 | -8.4 | -7.7 | -6.8 | -6.6 | -5.8 | -6.7 | -7.1 | -7.5 | -9.6 | -8.1 | -9.3 | -8.8 | ||
Diluted NI Avail to Com Stockholders Ann. | -9.6 | -8.4 | -7.7 | -6.8 | -6.6 | -5.8 | -6.7 | -7.1 | -7.5 | -9.6 | -8.1 | -9.3 | -8.8 | |
Basic EPS | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | -0.3 | -0.3 | -0.3 | |
Diluted EPS After ExtraOrdinary | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | -0.3 | -0.3 | -0.3 | |
Number Of Shares End | 189.2 | 172.5 | 141.3 | 108.4 | 98.6 | 87.8 | 74 | 68.3 | 57.6 | 44.8 | 30.8 | 28.4 | 28.4 | |
Net Income Continuing Discontinued Operations | -9.6 | -8.4 | -7.7 | -6.8 | -6.6 | -5.8 | -6.7 | -7.1 | -7.5 | -9.6 | -8.1 | -9.3 | -8.8 | |
Normalized Income | -8.6 | -7.6 | -7.2 | -6.3 | -6.1 | -5.3 | -6.4 | -6.7 | -7.1 | -9.1 | -7.6 | -8.7 | -8.3 | |
Interest Income | 1 | 0.8 | 0.6 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0 | 0.1 | 0.2 | |
Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Net Interest Income | 1 | 0.8 | 0.6 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0 | 0.1 | 0.2 | |
EBIT | -10.6 | -9.3 | -8.3 | -7.1 | -6.9 | -6.1 | -6.9 | -7.3 | -7.6 | -9.6 | -8.2 | -9.4 | -9.1 | |
EBITDA | -10.6 | -9.3 | -8.3 | -7.1 | -6.9 | -6.1 | -6.9 | -7.3 | -7.6 | -9.6 | -8.2 | -9.4 | -9.1 | |
Reconciled Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | ||||
Reconciled Depr. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Profit From Continuing Operations | -9.6 | -8.4 | -7.7 | -6.8 | -6.6 | -5.8 | -6.7 | -7.1 | -7.5 | -9.6 | -8.1 | -9.3 | -8.8 | |
Normalized EBITDA | -10.6 | -9.3 | -8.3 | -7.1 | -6.9 | -6.1 | -6.9 | -7.3 | -7.6 | -9.6 | -8.2 | -9.4 | -9.1 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
SELLAS Life Sciences Grp Inc competitor comparison and performance snapshot within industry
SELLAS Life Sciences Grp Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Annual Revenue SELLAS Life Sciences Grp Inc Annual Revenue is $0 Million which is growth of 0% YoY.
- POSITIVE
Annual Net Profit SELLAS Life Sciences Grp Inc Annual Net Profit is $-27 Million which is growth of 13.0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | 1 | 7.6 | 1.9 | |||||||||||
Cost Of Rev. Ann. | - | - | - | - | 0.1 | 0.2 | - | - | - | - | - | - | |||
Gross Profit Ann. | - | - | - | - | 0.9 | 7.4 | - | - | - | - | - | - | |||
Operating Exp. Ann. | -12.9% | 8.4% | 35.2 | 28.3 | 31.5 | 37.9 | 42.9 | 32.7 | 18.9 | 17.2 | 31.1 | 21.2 | 31.9 | 34.2 | |
Operating Profit Ann. | - | - | -35.2 | -28.3 | -31.5 | -37.9 | -42 | -25.3 | -17 | -17.2 | -31.1 | -21.2 | -31.9 | -34.2 | |
67.1% | - | 2.8 | 1.4 | 0.6 | 0.5 | 0.3 | 0 | 0 | 0.1 | -0.3 | -0.5 | -3.5 | -0.8 | ||
Other Exp. Ann. | - | - | - | - | 0.3 | 4.4 | 0.2 | -2.3 | 2.3 | -1.9 | 24.5 | -3.6 | |||
PBT Ann. | - | - | -32.5 | -26.9 | -30.9 | -37.3 | -41.3 | -20.9 | -16.8 | -19.4 | -29.1 | -23.5 | -10.9 | -38.6 | |
Tax Ann. | - | - | - | - | - | -0.2 | -0 | -0.1 | -1.4 | 0.3 | 0.2 | 0.4 | |||
- | - | -32.5 | -26.9 | -30.9 | -37.3 | -41.3 | -20.7 | -16.8 | -28 | -41.3 | -24.4 | -23.6 | -63.9 | ||
Diluted NI Avail to Com Stockholders Ann. | - | - | -32.5 | -26.9 | -30.9 | -37.3 | -41.3 | -20.7 | -16.8 | -28 | -41.3 | -24.4 | -23.6 | -63.9 | |
EPS Ann. | - | - | -0.3 | -0.5 | -1.3 | -2.1 | -1.3 | -2.1 | -10.9 | -157.5 | -522 | -3,540 | -12,300.1 | ||
Diluted EPS Ann. | - | - | -0.3 | -0.5 | -1.3 | -2.1 | -1.3 | -2.1 | -10.9 | -157.5 | -522 | -3,540 | -12,300.1 | ||
Number Of Shares End | 89.4% | 68.5% | 141.3 | 74 | 30.8 | 20.8 | 15.9 | 10.4 | 5.1 | 0.4 | 0.1 | 0 | 0 | ||
Total Exp. Ann. | -13% | 8.4% | 28.3 | 31.5 | 37.9 | 43 | 32.9 | 18.9 | 17.2 | 31.1 | 21.2 | 31.9 | 34.2 | ||
Net Income Continuing Discontinued Operations Ann. | - | - | -32.5 | -26.9 | -30.9 | -37.3 | -41.3 | -20.7 | -16.8 | -19.3 | -27.7 | -23.8 | -23.6 | -63.9 | |
Normalized Income Ann. | - | - | -29.7 | -24.9 | -29.3 | -35.3 | -39.9 | -18.4 | -16.4 | -16.5 | -21.5 | -20.7 | -24.5 | -35.6 | |
Interest Income Ann. | 67.1% | - | 2.8 | 1.4 | 0.6 | 0.5 | 0.3 | 0 | 0 | - | - | - | - | - | |
Interest Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
EBITDA Ann. | - | - | -35.2 | -28.3 | -31.5 | -37.9 | -41.6 | -20.9 | -16.5 | -19.5 | -28.8 | -23 | -7.2 | -37.5 | |
Reconciled Cost Of Rev. Ann. | - | - | - | - | 0.1 | 0.2 | - | - | - | - | - | - | |||
Reconciled Depr. Ann. | - | - | - | - | - | - | - | 0.3 | - | 0.1 | 0.4 | ||||
Profit From Continuing Operations Ann. | - | - | -32.5 | -26.9 | -30.9 | -37.3 | -41.3 | -20.7 | -16.8 | -19.3 | -27.7 | -23.8 | -11.1 | -39 | |
Normalized EBITDA Ann. | - | - | -35.2 | -28.3 | -31.5 | -37.9 | -42.3 | -29.7 | -16.9 | -14.9 | -33.4 | -19.3 | -56.2 | -30.3 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
-10.2%
2Y CAGR
-13.6%
3Y CAGR
-12.9%
5Y CAGR
8.4%
7Y CAGR
-1.3%
10Y CAGR
-1.9%
Operating Expenses Annual Cr is falling faster than historical averages.
SELLAS Life Sciences Grp Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund SELLAS Life Sciences Grp Inc Dec-2025 Total Shareholders Fund is $71 Million which is growth of 648.8% YoY.
- POSITIVE
Total Assets SELLAS Life Sciences Grp Inc Dec-2025 Total Assets is $78 Million which is growth of 303.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
55.3% | 11.2% | 78.3 | 19.4 | 6.2 | 20.9 | 26.3 | 46.1 | 16.6 | 16.9 | 33.5 | 65.8 | 82.1 | ||
-22.5% | -16.2% | 7.5 | 10 | 14.2 | 16.1 | 5.9 | 18.1 | 10.5 | 11.7 | 31.5 | 37.2 | 68.6 | ||
143.7% | 20.4% | 70.9 | 9.5 | -8 | 4.9 | 20.4 | 28 | 6.1 | 5.2 | 2.1 | 28.7 | 13.5 | ||
Total Capitalization Ann. | 143.7% | 20.4% | 70.9 | 9.5 | -8 | 4.9 | 20.4 | 28 | 6.1 | 5.3 | 4.7 | 28.7 | 13.5 | |
Tangible Assets Ann. | 187.6% | 27.6% | 69 | 7.6 | -9.9 | 2.9 | 18.4 | 20.4 | -1.5 | -5.2 | -17.4 | 0.6 | -14.5 | |
Working Capital Ann. | 214.1% | 22.6% | 68.2 | 6.8 | -10.6 | 2.2 | 18.1 | 24.6 | 3 | -0.1 | -11.5 | 7.1 | -3.5 | |
Invested Capital Ann. | 143.7% | 20.4% | 70.9 | 9.5 | -8 | 4.9 | 20.4 | 28 | 6.1 | 5.3 | 13.1 | 45.1 | 18.3 | |
Tangible Book Value Ann. | 187.6% | 27.6% | 69 | 7.6 | -9.9 | 2.9 | 18.4 | 20.4 | -1.5 | -5.2 | -17.4 | 0.6 | -14.5 | |
Borrowings Ann. | 3.6% | 0% | 1 | 1 | 0.9 | 0.9 | 0.8 | 1 | 0.2 | - | 11 | 16.4 | 4.7 | |
Net Debt Ann. | - | - | - | - | - | - | - | - | - | - | 8.7 | - | - | |
Share Issued Ann. | 93.9% | 60.7% | 153.1 | 74 | 32.1 | 21 | 15.9 | 14.3 | 5.1 | 0.4 | 0.1 | 0 | 0 | |
Number Of Shares End | 89.4% | 68.5% | 141.3 | 74 | 30.8 | 20.8 | 15.9 | 10.4 | 5.1 | 0.4 | 0.1 | 0 | 0 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
303.6%
2Y CAGR
255.4%
3Y CAGR
55.3%
5Y CAGR
11.2%
7Y CAGR
24.5%
10Y CAGR
-0.5%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
-26.3%
2Y CAGR
-28.5%
3Y CAGR
-23.3%
5Y CAGR
-10.7%
7Y CAGR
2.2%
10Y CAGR
-18.9%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
646.3%
3Y CAGR
143.7%
5Y CAGR
20.4%
7Y CAGR
45.2%
10Y CAGR
18%
Total ShareHolders Funds Annual growth is higher than historical averages.
SELLAS Life Sciences Grp Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Book Value Per Share SELLAS Life Sciences Grp Inc Book Value Per Share is $0 which is growth of 32.5% YoY.
- NEUTRAL
ROE SELLAS Life Sciences Grp Inc ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | -240.78% | -274.94% | -174.94% | -57.24% | -53.74% | -166.75% | -163.56% | -49.18% | -31.83% | -78.58% | |
ROE Ann. % | - | - | - | -4,147.88% | - | -327.81% | -85.70% | -98.87% | -493.05% | -1,127.85% | -159.01% | -111.69% | -252.72% | |
ROIC % | - | - | - | -51.4 | - | -95.5 | -27.1 | -19.6 | -86 | -112.4 | 8.3 | -11.9 | -71.8 | |
OPM Ann. % | - | - | - | - | - | -4,195.00% | -332.82% | -893.79% | - | - | - | - | - | |
Inventory Turnover Ratio Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Asset Turnover Ann. % | - | - | - | - | - | 0 | 0.2 | 0.1 | - | - | - | - | - | |
Working Capital Turnover Ann. | - | - | 0.5 | 0.4 | 0.1 | |||||||||
Quick Ratio Ann. | - | - | - | 1.5 | 0.2 | 1.1 | 4.3 | 3 | 1.4 | 0.9 | 0.1 | 0.6 | 0.5 | |
Current Ratio Ann. | - | - | - | 1.7 | 0.2 | 1.1 | 4.6 | 3 | 1.6 | 1 | 0.5 | 1.2 | 0.9 | |
Interest Coverage Ratio Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
LT Debt To Equity Ann. | - | - | - | 0.1 | - | 0.1 | 0 | 0 | - | - | 1.3 | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
SELLAS Life Sciences Grp Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Cash From Operating Activity SELLAS Life Sciences Grp Inc Cash From Operating Activity is $-28 Million which is growth of 19.8% YoY.
- NEUTRAL
Net Cash Flow SELLAS Life Sciences Grp Inc Net Cash Flow is $0 Million which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -28.4 | -35.4 | -31.4 | -23.8 | -26 | -10.4 | -17.6 | -30.4 | -11 | -33.2 | -38.8 | ||
- | - | - | -5.5 | -4.5 | - | - | - | 1.8 | -0 | -0.4 | ||||
53% | 17.6% | 86.3 | 46.8 | 22.3 | 24.1 | 12.1 | 38.4 | 19.6 | 23.1 | 5.5 | 34.3 | 43.8 | ||
Cash Plus Cash Eqv. End Of Year Ann. | 61.1% | 15.2% | 71.9 | 14 | 2.6 | 17.2 | 21.5 | 35.4 | 7.4 | 5.5 | 2.3 | 18.1 | 29.7 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | 15.6% | 57.9 | 11.4 | -14.6 | -4.2 | -14 | 28 | 1.9 | -7.3 | -3.6 | -11.7 | 6.1 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | -13.3% | 13.6% | 14 | 2.6 | 17.2 | 21.5 | 35.4 | 7.4 | 5.5 | 12.8 | 6 | 29.7 | 23.7 | |
Income Tax Paid Supplemental Data Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Interest Paid Supplemental Data Ann. | - | - | - | - | - | - | - | - | 0.3 | - | 0.6 | 0.5 | ||
Capex Ann. | - | - | - | - | -5.5 | -4.5 | - | - | - | - | - | -0 | -0.2 | |
Issuance Of Capital Stock Ann. | -1.3% | -4.8% | 23.1 | 46.2 | 22.2 | 24 | 9 | 29.6 | 16 | 31.2 | 6 | 33.6 | 47.7 | |
Issuance Of Debt Ann. | - | - | - | - | - | - | - | - | - | - | 23.4 | - | ||
Repayment Of Debt Ann. | - | - | - | - | - | - | - | - | -7.6 | -0.5 | -5.6 | -3.9 | ||
Repurchase Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Free Cash Flow Ann. | - | - | -28.4 | -35.4 | -36.9 | -28.3 | -26 | -10.4 | -17.6 | -30.4 | -11 | -33.2 | -39 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
84.4%
2Y CAGR
96.7%
3Y CAGR
53%
5Y CAGR
17.6%
7Y CAGR
20.7%
10Y CAGR
7%
Cash from Financing Annual Activity growth is higher than historical averages.